Enhanced stratification of COPD patients via integration of a digitally enabled biomarker Point-of-Care test within a Remote Patient Monitoring tool

通过在远程患者监测工具中集成数字化生物标志物即时检测，增强 COPD 患者的分层

• 批准号: 10098600
• 金额: $ 62.58万
• 依托单位: PROAXSIS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10098600
• 关键词: Enhanced; stratification; COPD; patients; via

The enzyme Neutrophil Elastase (NE) is associated with the severity of several respiratory diseases, including Chronic Obstructive Pulmonary Disease (COPD), where repeated cycles of infection and inflammation leads to active NE release from immune cells, causing lung damage. Active NE is predictive of lung function loss and is the most informative biomarker to monitor disease activity.ProAxsis has developed a novel point-of-care test (NEATstik) which allows active NE to be quickly measured within 10 minutes. Researchers in Dundee have shown that a positive NEATstik test identifies patients suffering from a lung bacterial infection, who are most likely to benefit from antibiotics. Additionally, they used NEATstik to identify patients at highest risk of suffering from exacerbations over the following year. Thus, NEATstik can support appropriate antibiotic prescribing, and monitoring of their effect, to ensure that respiratory disease patients receive the treatment that is most likely to work for them.An additional key advantage of NEATstik is that it could be used in the patient's home, thereby avoiding unnecessary trips to hospital, a key consideration in the post-COVID environment. To make this viable, enhancements are needed for the sample processing required for conduct of the test. Further valuable information could be gained if the NEATstik result was combined with other respiratory health measures. This is a collaborative project between ProAxsis Limited, who developed NEATstik, the Centre for Process and Innovation (CPI), a world-renowned product engineering expert centre and Wanda Health, specialists in integrating new technologies into remote patient monitoring systems. Together, the partners will significantly enhance the sample processing required for NEATstik, and integrate the test alongside multiple other respiratory health measures into a remote patient monitoring tool, allowing patients to conduct the test at home, and their healthcare professionals to observe the NEATstik test result alongside other important health data.

中性粒细胞弹性蛋白酶 (NE) 与多种呼吸系统疾病的严重程度相关，包括慢性阻塞性肺疾病 (COPD)，感染和炎症的反复循环导致免疫细胞主动释放 NE，从而导致肺部损伤。活动性 NE 可预测肺功能丧失，并且是监测疾病活动性的信息最丰富的生物标志物。ProAxsis 开发了一种新型即时护理测试 (NEATstik)，可在 10 分钟内快速测量活动性 NE。邓迪的研究人员表明，NEATstik 测试呈阳性可识别患有肺部细菌感染的患者，这些患者最有可能受益于抗生素。此外，他们还使用 NEATstik 来识别在接下来的一年中病情恶化风险最高的患者。因此，NEATstik 可以支持适当的抗生素处方并监测其效果，以确保呼吸系统疾病患者接受最有可能对其有效的治疗。NEATstik 的另一个主要优势是它可以在患者家中使用，从而避免不必要的去医院，这是后疫情时代的一个关键考虑因素。为了使其可行，需要增强进行测试所需的样品处理。如果 NEATstik 结果与其他呼吸系统健康指标相结合，可以获得更多有价值的信息。这是开发 NEATstik 的 ProAxsis Limited、世界著名的产品工程专家中心流程与创新中心 (CPI) 和将新技术集成到远程患者监护系统的专家万达健康 (Wanda Health) 之间的合作项目。合作伙伴将共同显着增强 NEATstik 所需的样本处理，并将该测试与多种其他呼吸健康指标一起集成到远程患者监测工具中，使患者能够在家中进行测试，并让他们的医疗保健专业人员观察 NEATstik 测试结果以及其他重要的健康数据。